Background Home-based exercise program showed the potential in improving physical function of chronic kidney disease patients, and it might need low associated costs. We conducted a systematic review and meta-analysis to explore the impact of home-based exercise program on physical function of chronic kidney disease patients. Methods PubMed, EMBASE, Web of science, EBSCO, and Cochrane library databases were systematically searched. This meta-analysis included randomized controlled trials (RCTs) assessing the effect of home-based exercise program on physical function of chronic kidney disease patients. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. The primary outcomes were 6-min walk test and grip strength change. Results Seven RCTs were included in the meta-analysis. Overall, compared with control intervention in chronic kidney disease patients, home-based exercise program could significantly improve 6-min walk test (MD=79.01; 95% CI=22.39–135.62; P=0.006) and grip strength (SMD=0.52; 95% CI=0.14–0.89; P=0.007), but showed no impact on pain scores (SMD=−1.43; 95% CI=−3.75 to 0.88; P=0.22), Kidney Disease Quality of life including symptom/problem list (SMD=1.92; 95% CI=−1.06 to 4.90; P=0.21), effects of kidney disease (SMD=−3.69; 95% CI=−8.56 to 1.19; P=0.14), or burden of kidney disease (SMD=1.04; 95% CI=−0.75 to 2.82; P=0.26). Conclusions Home-based exercise program might improve physical function for chronic kidney disease, and more RCTs should be conducted to confirm this issue.

Paricalcitol and calcitriol are widely used for the treatment of secondary hyperparathyroidism in dialysis patients. We conducted a systematic review and meta-analysis to compare the efficacy and safety of paricalcitol and calcitriol for secondary hyperparathyroidism in dialysis patients. PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases were systematically searched. Randomized controlled trials (RCT) assessing the efficacy of paricalcitol and calcitriol for secondary hyperparathyroidism in dialysis patients are included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. Meta-analysis was carried out using the random-effect model. Six randomized controlled trials are included in the meta-analysis. Overall, compared with calcitriol treatment for secondary hyperparathyroidism in dialysis patients, paricalcitol treatment has comparable ≥50% reduction of parathyroid hormone (risk ratio [RR] = 1.33; 95% CI = 0.93-1.91;